New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
07:05 EDTDGXQuest Diagnostics plans to sell HemoCue diagnostic products business
Quest Diagnostics announced that it plans to sell its HemoCue diagnostic products business, as part of the company's strategy to refocus on diagnostic information services. HemoCue develops, produces and markets point-of-care testing systems. As a result, Quest Diagnostics will report 2012 and 2011 results for HemoCue and its OralDNA products business, which was sold in December, 2012, as discontinued operations in its report of fourth quarter 2012 results, and take related after-tax charges in discontinued operations for the estimated asset impairment associated with HemoCue and the loss on sale associated with OralDNA, totaling $89.5M, or 56c per diluted share, in the period. The company's consolidated income statements for FY12 and 2011 will present the operating results of HemoCue and OralDNA as discontinued operations. As such, results from continuing operations will be reduced as follows: Revenues by $117M in 2012 and $119M in 2011; Operating income by $11M in 2012 and $8M in 2011; Net income from continuing operations by $15M in 2012 and $13M in 2011; and EPS by 9c in 2012 and 8c in 2011.
News For DGX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
10:00 EDTDGXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:51 EDTDGXQuest Diagnostics upgraded to Buy at Canaccord
Subscribe for More Information
06:36 EDTDGXQuest Diagnostics upgraded to Buy from Hold at Canaccord
Subscribe for More Information
March 2, 2015
10:00 EDTDGXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:56 EDTDGXQuest Diagnostics initiated with an Equal Weight at Barclays
Subscribe for More Information
February 26, 2015
10:00 EDTDGXOn The Fly: Analyst Downgrade SummaryStarz
Subscribe for More Information
07:24 EDTDGXQuest Diagnostics downgraded to Buy from Conviction Buy at Goldman
Goldman removed Quest Diagnostics (DGX) from the Conviction Buy List and added LabCorp (LH) to the list. The firm believes LabCorp will have higher average organic growth and earnings growth, and views its valuation as more attractive. The firm rates Quest Diagnostics a Buy with a $77 price target.
February 23, 2015
09:59 EDTDGXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Antofagasta (ANFGY) downgraded to Sell from Neutral at Goldman... Arch Coal (ACI) downgraded to Sell from Buy at Argus... BHP Billiton (BHP) downgraded to Equal Weight from Overweight at Morgan Stanley... Beazer Homes (BZH) downgraded to Neutral from Buy at Compass Point... Boeing (BA) downgraded to Sell from Neutral at Goldman... Century Communities (CCS) downgraded to Neutral from Overweight at JPMorgan... CyberArk (CYBR) downgraded to Underweight from Neutral at JPMorgan... DirecTV (DTV) downgraded to Hold from Buy at Brean Capital... Enerplus (ERF) downgraded to Hold from Buy at Desjardins... Fiserv (FISV) downgraded to Neutral from Buy at Monness Crespi... GP Strategies (GPX) downgraded to Neutral from Buy at B. Riley... Interactive Brokers (IBKR) downgraded to Market Perform at Keefe Bruyette... MRC Global (MRC) downgraded at BB&T... Precision Castparts (PCP) downgraded to Neutral from Buy at Goldman... Quest Diagnostics (DGX) downgraded at BofA/Merrill... Rio Tinto (RIO) downgraded to Equal Weight from Overweight at Morgan Stanley... Roth Capital downgraded Spectrum (SPPI) on court case loss... Royal Dutch Shell (RDS.A) downgraded to Sector Perform from Outperform at Howard Weil... Ryland Group (RYL) downgraded to Neutral from Buy at Compass Point... Salix (SLXP) downgraded to Market Perform from Outperform at Leerink... Standard Pacific (SPF) downgraded to Neutral from Buy at Compass Point... Superior Energy (SPN) downgraded to Neutral from Outperform at Credit Suisse... Transocean (RIG) downgraded to Negative from Neutral at Susquehanna... Vale (VALE) downgraded to Equal Weight from Overweight at Morgan Stanley.
08:18 EDTDGXQuest Diagnostics downgraded at BofA/Merrill
Subscribe for More Information
06:24 EDTDGXQuest Diagnostics downgraded to Underperform from Neutral at BofA/Merrill
February 20, 2015
07:08 EDTDGXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use